ATE394423T1
(de)
|
1998-12-07 |
2008-05-15 |
Sod Conseils Rech Applic |
Analoge des glucagon ähnlichen peptides-1 (glp-1)
|
JP3702181B2
(ja)
*
|
1998-12-07 |
2005-10-05 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1の類似体
|
EP1305338A2
(en)
*
|
2000-08-02 |
2003-05-02 |
Theratechnologies Inc. |
Modified peptides with increased potency
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
AU2002213925A1
(en)
|
2000-09-18 |
2002-03-26 |
Osteometer Biotech As |
Use of glp-1 and flp-2 peptides for treatment of bone disorders
|
DE60136958D1
(de)
|
2000-12-01 |
2009-01-22 |
Takeda Pharmaceutical |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
GB0100196D0
(en)
*
|
2001-01-04 |
2001-02-14 |
Anmat Technology Ltd |
Peptides
|
JP2005501058A
(ja)
*
|
2001-07-31 |
2005-01-13 |
ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ |
Glp−1、exendin−4、そのペプチド・アナログ及びその使用
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
JP2005514337A
(ja)
*
|
2001-10-18 |
2005-05-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒトグルカゴン様ペプチド−1模倣体、並びに糖尿病および関連疾患の処置におけるその使用
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
AU2003271452A1
(en)
*
|
2002-09-25 |
2004-04-19 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
CN100354306C
(zh)
*
|
2002-10-11 |
2007-12-12 |
株式会社三和化学研究所 |
Glp-1衍生物及其经粘膜吸收的制剂
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
EP2067483A1
(en)
*
|
2003-02-19 |
2009-06-10 |
Ipsen Pharma |
Analogues of GLP-1
|
WO2004087910A1
(ja)
*
|
2003-03-28 |
2004-10-14 |
National Institute Of Agrobiological Sciences |
組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
ES2375056T3
(es)
|
2003-06-03 |
2012-02-24 |
Novo Nordisk A/S |
Composiciones pept�?dicas farmacéuticas estabilizadas.
|
EP2292254A3
(en)
|
2003-06-03 |
2011-12-14 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
JP2007514752A
(ja)
*
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1医薬組成物
|
EP2210900A3
(en)
*
|
2003-12-16 |
2010-08-11 |
Ipsen Pharma |
Analogues of GLP-1
|
DE602004026113D1
(de)
|
2003-12-18 |
2010-04-29 |
Novo Nordisk As |
Glp-1-verbindungen
|
EP1709071A4
(en)
*
|
2004-01-08 |
2007-05-30 |
Theratechnologies Inc |
PEPTIDE ANALOGUES 1 LIKE LONG-ACTING GLUCAGON-LIKE
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
CN101010339B
(zh)
*
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
WO2006037810A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted glp-1 compounds
|
EP1841448A2
(en)
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Pharmaceutical compositions and methods for restoring beta-cell mass and function
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US8603972B2
(en)
|
2005-03-18 |
2013-12-10 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
NZ565535A
(en)
*
|
2005-06-30 |
2011-03-31 |
Ipsen Pharma Sas |
GLP-1 pharmaceutical compositions
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
ES2507098T3
(es)
|
2005-11-07 |
2014-10-14 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
|
CA2800389A1
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
CA2651855C
(en)
|
2006-05-30 |
2011-08-02 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
EP2035451B1
(en)
*
|
2006-06-23 |
2010-05-05 |
F.Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis
|
GB0612669D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Leeds |
Biomarkers for preeclampsia
|
MX2009001043A
(es)
|
2006-08-08 |
2009-02-06 |
Sanofi Aventis |
Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
MEP8509A
(en)
|
2006-09-07 |
2011-12-20 |
|
Combination treatment for diabetes mellitus
|
KR101247665B1
(ko)
*
|
2006-12-29 |
2013-04-02 |
입센 파마 에스.에이.에스 |
Glp―1 약학 조성물
|
CA2674209A1
(en)
*
|
2006-12-29 |
2008-07-10 |
Ipsen Pharma S.A.S. |
Glp-1 pharmaceutical compositions
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
EP2487184A1
(en)
|
2007-02-15 |
2012-08-15 |
Indiana University Research and Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
ES2672770T3
(es)
|
2007-09-05 |
2018-06-18 |
Novo Nordisk A/S |
Derivados del péptido-1 similar al glucagón y su uso farmacéutico
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
JP5606314B2
(ja)
|
2007-09-05 |
2014-10-15 |
ノボ・ノルデイスク・エー/エス |
A−b−c−d−で誘導体化されたペプチドとその治療用途
|
EP2200626A4
(en)
*
|
2007-09-07 |
2012-02-15 |
Ipsen Pharma Sas |
ANALOGUE OF EXENDIN-4 AND EXENDIN-3
|
CN101835794A
(zh)
|
2007-10-27 |
2010-09-15 |
霍夫曼-拉罗奇有限公司 |
使用固相和溶液相组合技术的促胰岛素肽合成法
|
CA2702289A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
CN101903400B
(zh)
*
|
2007-12-11 |
2013-12-18 |
霍夫曼-拉罗奇有限公司 |
使用固相和液相组合技术的促胰岛素肽合成
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
EP2300037B1
(en)
|
2008-06-17 |
2016-03-30 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
PE20100056A1
(es)
*
|
2008-06-17 |
2010-01-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon como agonistas gip
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
RU2526804C2
(ru)
|
2008-08-06 |
2014-08-27 |
Ново Нордиск Хелс Кеа Аг |
Конъюгированные белки с пролонгированным действием in vivo
|
CN102171243A
(zh)
*
|
2008-08-07 |
2011-08-31 |
益普生制药股份有限公司 |
N-端修饰的葡萄糖依赖性促胰岛素多肽(gip)类似物
|
CN103641906A
(zh)
*
|
2008-08-07 |
2014-03-19 |
益普生制药股份有限公司 |
葡萄糖依赖性促胰岛素多肽类似物
|
EP2915538A3
(en)
*
|
2008-08-07 |
2015-10-14 |
Ipsen Pharma S.A.S. |
Truncated analogues of glucose-dependent insulinotropic polypeptide
|
EP2328922A4
(en)
*
|
2008-08-07 |
2013-01-02 |
Ipsen Pharma Sas |
ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE
|
TW201012829A
(en)
*
|
2008-09-22 |
2010-04-01 |
Ipsen Mfg Ireland Ltd |
Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
|
KR20110126591A
(ko)
|
2008-12-15 |
2011-11-23 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
BRPI0823377A2
(pt)
|
2008-12-15 |
2016-09-27 |
Zealand Pharma As |
análogos de glucagon
|
CA2747109A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
CN102325539A
(zh)
|
2008-12-19 |
2012-01-18 |
印第安纳大学研究及科技有限公司 |
基于酰胺的胰高血糖素超家族肽前药
|
US20100183876A1
(en)
*
|
2008-12-23 |
2010-07-22 |
Hell Andre |
Process for the Preparation of a Peptide Powder Form
|
CA2747332C
(en)
|
2008-12-23 |
2015-01-27 |
F. Hoffmann-La Roche Ag |
Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
|
CN102292349B
(zh)
|
2009-01-22 |
2016-04-13 |
诺沃—诺迪斯克保健股份有限公司 |
稳定的生长激素化合物
|
EP2216042A1
(en)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP-1 analogues pharmaceutical compositions
|
CA2759468A1
(en)
*
|
2009-05-01 |
2010-11-04 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
MX2011013625A
(es)
*
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
PE20121130A1
(es)
|
2009-07-13 |
2012-08-30 |
Zealand Pharma As |
Analogos de glucagon acilados
|
CN105963710A
(zh)
|
2009-08-06 |
2016-09-28 |
诺沃—诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
ES2443016T3
(es)
|
2009-08-26 |
2014-02-17 |
Sanofi |
Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
|
EP3323423B1
(en)
|
2009-09-28 |
2020-06-17 |
Intarcia Therapeutics, Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
EP2491054A2
(en)
|
2009-10-22 |
2012-08-29 |
Cadila Healthcare Limited |
Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
|
CA2787895A1
(en)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Stable growth hormone compounds
|
TWI508737B
(zh)
|
2010-01-22 |
2015-11-21 |
諾佛 儂迪克股份有限公司 |
具有延長的活體內功效的生長激素
|
JP2013518115A
(ja)
|
2010-01-27 |
2013-05-20 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
KR20130093470A
(ko)
|
2010-04-30 |
2013-08-22 |
가부시키가이샤산와카가쿠켄큐쇼 |
생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
US20110313131A1
(en)
|
2010-06-21 |
2011-12-22 |
Christelle Carl |
Reversed phase hplc purification of a glp-1 analogue
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
AP2013006671A0
(en)
*
|
2010-06-24 |
2013-01-31 |
Zealand Pharma As |
Glucagon analogues
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
KR101925620B1
(ko)
|
2010-12-16 |
2018-12-05 |
노보 노르디스크 에이/에스 |
Glp-1 아고니스트 및 n-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
|
CN103458920B
(zh)
|
2010-12-22 |
2016-07-06 |
印第安那大学科技研究公司 |
表现出gip受体活性的胰高血糖素类似物
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120050A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
US9266940B2
(en)
|
2011-04-12 |
2016-02-23 |
Novo Nordisk A/S |
Double-acylated GLP-1 derivatives
|
KR20140043793A
(ko)
|
2011-06-22 |
2014-04-10 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-작용물질
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
CN103930134B
(zh)
|
2011-07-18 |
2016-12-21 |
阿茨生物股份有限公司 |
长效促黄体激素(lh)化合物
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
DK2827845T3
(en)
|
2012-03-22 |
2019-04-01 |
Novo Nordisk As |
COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
|
EP2827885B1
(en)
|
2012-03-22 |
2018-08-15 |
Novo Nordisk A/S |
Compositions of glp-1 peptides and preparation thereof
|
US10100097B2
(en)
|
2012-05-03 |
2018-10-16 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
US9745359B2
(en)
|
2012-05-18 |
2017-08-29 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
EP2873422A4
(en)
|
2012-07-10 |
2015-12-30 |
Takeda Pharmaceutical |
PHARMACEUTICAL PREPARATION FOR INJECTION
|
KR101848303B1
(ko)
|
2012-07-10 |
2018-04-13 |
삼성전자주식회사 |
전력 전송을 제어하기 위한 방법 및 이를 위한 전력 송신기
|
DK2875043T3
(en)
|
2012-07-23 |
2017-03-27 |
Zealand Pharma As |
glucagon
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
WO2014064215A1
(en)
|
2012-10-24 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
|
WO2014077801A1
(en)
|
2012-11-13 |
2014-05-22 |
Ipsen Pharma S.A.S. |
Purification process for preparing highly pure taspoglutide
|
WO2014077802A1
(en)
|
2012-11-13 |
2014-05-22 |
Ipsen Pharma S.A.S. |
Purification method of a glp-1 analogue
|
JP6464145B2
(ja)
|
2013-04-05 |
2019-02-06 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
成長ホルモン化合物製剤
|
US9738697B2
(en)
|
2013-06-23 |
2017-08-22 |
Wisconsin Alumni Research Foundation |
Alpha/beta-polypeptide analogs of glucagon-like peptide-1
|
CN103536907B
(zh)
*
|
2013-07-18 |
2015-10-21 |
上海交通大学医学院附属瑞金医院 |
利拉鲁肽在骨质疏松治疗药物中的应用
|
EA034322B1
(ru)
|
2013-10-17 |
2020-01-28 |
Зилэнд Фарма А/С |
Ацилированные аналоги глюкагона
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2015067716A1
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
EP3077008B1
(en)
|
2013-12-06 |
2023-10-04 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
JP2017502003A
(ja)
*
|
2013-12-13 |
2017-01-19 |
メディミューン リミテッド |
プロテアーゼ耐性ペプチド
|
CN106132985B
(zh)
|
2014-04-07 |
2020-10-13 |
诺和诺德股份有限公司 |
双酰化glp-1化合物
|
EP3189072B1
(en)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Gip peptide analogues
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
MX2017005457A
(es)
|
2014-10-29 |
2017-07-04 |
Zealand Pharma As |
Metodos y compuestos agonistas de gip.
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
AU2016270984B2
(en)
|
2015-06-03 |
2021-02-25 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
KR20240037175A
(ko)
|
2016-05-16 |
2024-03-21 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
IL307966A
(en)
|
2017-01-03 |
2023-12-01 |
Intarcia Therapeutics Inc |
Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
EP4361173A2
(en)
|
2017-05-31 |
2024-05-01 |
University of Copenhagen |
Long-acting gip peptide analogues
|
PL3746111T3
(pl)
|
2018-02-02 |
2024-01-15 |
Novo Nordisk A/S |
Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
|
CA3094820A1
(en)
*
|
2018-03-23 |
2019-09-26 |
Carmot Therapeutics, Inc. |
Modulators of g-protein coupled receptors
|
CA3095988A1
(en)
|
2018-04-05 |
2019-10-10 |
Sun Pharmaceutical Industries Limited |
Novel glp-1 analogues
|
WO2019200594A1
(zh)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
酰化的glp-1衍生物
|
SG11202103586UA
(en)
|
2018-10-11 |
2021-05-28 |
Intarcia Therapeutics Inc |
Human amylin analog polypeptides and methods of use
|
CN109400695B
(zh)
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
CN113366014A
(zh)
|
2018-12-03 |
2021-09-07 |
安泰博医药 |
经修饰的gip肽类似物
|
WO2022157747A2
(en)
|
2021-01-25 |
2022-07-28 |
Mylan Ireland Limited |
Pharmaceutical peptide compositions and methods of preparation thereof
|
CN114621339B
(zh)
*
|
2021-12-28 |
2022-09-23 |
北京惠之衡生物科技有限公司 |
一种长效glp-1衍生物
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|